Literature DB >> 15616008

Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.

Yanjun Liu1, Yuichi Nakagawa, Ying Wang, Reiko Sakurai, Pinky V Tripathi, Kabirullah Lutfy, Theodore C Friedman.   

Abstract

Excess tissue glucocorticoid action may contribute to the hyperglycemia and insulin resistance associated with type 2 diabetes, but the associated mechanisms are poorly understood. 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) converts inactive 11-dehydrocorticosterone into active corticosterone, thus amplifying glucocorticoid receptor-mediated tissue glucocorticoid action, particularly in the liver. To examine the role of tissue glucocorticoid action in type 2 diabetes, we analyzed expression of glucocorticoid receptor and 11beta-HSD1 and their regulation by endogenous hormones in vivo and in vitro in hepatocytes from db/db mice (a model of type 2 diabetes). We observed positive relations between expression of both glucocorticoid receptor and 11beta-HSD1 in liver and insulin sensitivity and expression of PEPCK mRNA in db/db mice and db/+ controls. Increased expression of glucocorticoid receptor and 11beta-HSD1 in the liver of db/db mice was correlated with elevated circulating levels of corticosterone, insulin, and blood glu-cose. Treatment of db/db mice with glucocorticoid antagonist RU486 reversed the increases in the expression of glucocorticoid receptor and 11beta-HSD1 within the liver and attenuated the phenotype of type 2 diabetes. Addition of corticosterone to db/db mouse primary hepatocytes activated expression of glucocorticoid receptor, 11beta-HSD1, and PEPCK, and these effects were abolished by RU486. Incubation of primary hepatocytes with increasing concentrations of glucose caused dose-dependent increases in glucocorticoid receptor and 11beta-HSD1 expression, whereas insulin did not affect the expression of 11beta-HSD1 and glucocorticoid receptor in primary hepatocytes. These findings suggest that activation of glucocorticoid receptor and 11beta-HSD1 expression within the liver may contribute to the development of type 2 diabetes in db/db mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15616008     DOI: 10.2337/diabetes.54.1.32

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  36 in total

1.  G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome.

Authors:  Ibolya Czegle; Miklós Csala; József Mandl; Angelo Benedetti; István Karádi; Gábor Bánhegyi
Journal:  World J Hepatol       Date:  2012-04-27

Review 2.  Minireview: new molecular mediators of glucocorticoid receptor activity in metabolic tissues.

Authors:  Rucha Patel; Jasmine Williams-Dautovich; Carolyn L Cummins
Journal:  Mol Endocrinol       Date:  2014-04-25

3.  Interplay between H6PDH and 11β-HSD1 implicated in the pathogenesis of type 2 diabetes mellitus.

Authors:  Fan Yao; Li Chen; Zheng Fan; Fei Teng; Yali Zhao; Fengying Guan; Ming Zhang; Yanjun Liu
Journal:  Bioorg Med Chem Lett       Date:  2017-07-15       Impact factor: 2.823

4.  Tissue-specific dysregulation of hexose-6-phosphate dehydrogenase and glucose-6-phosphate transporter production in db/db mice as a model of type 2 diabetes.

Authors:  Y Wang; Y Nakagawa; L Liu; W Wang; X Ren; A Anghel; K Lutfy; T C Friedman; Y Liu
Journal:  Diabetologia       Date:  2010-11-04       Impact factor: 10.122

5.  Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients.

Authors:  Esther Torrecilla; Gumersindo Fernández-Vázquez; David Vicent; Franco Sánchez-Franco; Ana Barabash; Lucio Cabrerizo; Andrés Sánchez-Pernaute; Antonio J Torres; Miguel Angel Rubio
Journal:  Obes Surg       Date:  2012-03       Impact factor: 4.129

6.  Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop.

Authors:  Rucha Patel; Angie L Bookout; Lilia Magomedova; Bryn M Owen; Giulia P Consiglio; Makoto Shimizu; Yuan Zhang; David J Mangelsdorf; Steven A Kliewer; Carolyn L Cummins
Journal:  Mol Endocrinol       Date:  2014-12-11

Review 7.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

8.  Suppression of hepatic glucose production by human neutrophil alpha-defensins through a signaling pathway distinct from insulin.

Authors:  Hui-Yu Liu; Qu Fan Collins; Fatiha Moukdar; Degen Zhuo; Jianmin Han; Tao Hong; Sheila Collins; Wenhong Cao
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

9.  The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse.

Authors:  Rashmi Kumari; Lisa B Willing; Shyama D Patel; J Kyle Krady; William J Zavadoski; E Michael Gibbs; Susan J Vannucci; Ian A Simpson
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-28       Impact factor: 6.200

10.  Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.

Authors:  Yanjun Liu; Yuichi Nakagawa; Ying Wang; Limei Liu; Hongwei Du; Wei Wang; Xiuhai Ren; Kabirullah Lutfy; Theodore C Friedman
Journal:  J Mol Endocrinol       Date:  2008-06-04       Impact factor: 5.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.